Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry

被引:20
|
作者
Spencer, K [1 ]
机构
[1] Harold Wood Hosp, Dept Clin Biochem, Endocrine Unit, Romford RM3 0BE, Essex, England
关键词
trisomy; 21; prenatal screening; free beta-hCG; PAPP-A;
D O I
10.1002/pd.312
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Over the past three years approximately 12 000 women have been screened in the first trimester through Our OSCAR programme, which utilizes fetal NT and maternal serum free beta-hCG and PAPP-A. During this time 30 cases of Down syndrome were identified either prenatally or postnatally. Using an established procedure the accuracy of predicted risk for Down syndrome was assessed in a population of 30 cases of Down syndrome and 11 758 unaffected pregnancies. The correlation between predicted risk and prevalence of Down syndrome was very high (r=0.9995). It is concluded that risks produced by the Fetal Medicine Foundation combined risk algorithm agree very closely with Down syndrome prevalence and can be used With confidence when counselling women of their risk. Copyright (C) 2002 John Wiley Sons. Ltd.
引用
收藏
页码:244 / 246
页数:3
相关论文
共 50 条
  • [1] First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency
    Orlandi, F
    Damiani, G
    Hallahan, TW
    Krantz, DA
    Macri, JN
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1997, 10 (06) : 381 - 386
  • [2] First-Trimester Nuchal Translucency Screening to Detect Down Syndrome
    Smith, DeAnn
    NEWBORN AND INFANT NURSING REVIEWS, 2008, 8 (01) : E1 - E6
  • [3] The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy
    Spencer, K
    Bindra, R
    Cacho, AM
    Nicolaides, KH
    PRENATAL DIAGNOSIS, 2004, 24 (03) : 169 - 173
  • [4] First-trimester nuchal translucency screening for fetal aneuploidy
    Sherer, DM
    Manning, FA
    AMERICAN JOURNAL OF PERINATOLOGY, 1999, 16 (03) : 103 - 120
  • [5] First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers
    Muller, F
    Benattar, C
    Audibert, F
    Roussel, N
    Dreux, S
    Cuckle, H
    PRENATAL DIAGNOSIS, 2003, 23 (10) : 833 - 836
  • [6] ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome
    Laigaard, Jennie
    Spencer, Kevin
    Christiansen, Michael
    Cowans, Nicholas J.
    Larsen, Severin Olesen
    Pedersen, Bent Norgaard
    Wewer, Ulla M.
    PRENATAL DIAGNOSIS, 2006, 26 (10) : 973 - 979
  • [7] Diagnosis of fetal acrania during the first trimester nuchal translucency screening for Down syndrome
    Cheng, CC
    Lee, FK
    Lin, HW
    Shih, JC
    Tsai, MS
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 80 (02) : 139 - 144
  • [8] The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical makers of aneuploidy
    Spencer, K
    Cicero, S
    Atzei, A
    Otigbah, C
    Nicolaides, KH
    PRENATAL DIAGNOSIS, 2005, 25 (10) : 927 - 929
  • [9] The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness
    Hacivelioglu, S.
    Uysal, A.
    Gungor, A. N. Cakir
    Gencer, M.
    Cakir, D. U.
    Cosar, E.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2015, 42 (01) : 32 - 35
  • [10] First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population
    Brizot, ML
    Carvalho, MHB
    Liao, AW
    Reis, NSV
    Armbruster-Moraes, E
    Zugaib, M
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2001, 18 (06) : 652 - 655